Immunovant (IMVT) Is Up 14.0% After Roivant-Backed $550 Million Equity Raise For IMVT-1402 - Has The Bull Case Changed? [Yahoo! Finance]
Roivant Sciences Ltd. (ROIV)
Company Research
Source: Yahoo! Finance
per share, to help fund development and a potential commercial launch of its lead candidate IMVT-1402 for Graves' disease and other autoimmune conditions. A striking element of the deal is controlling shareholder Roivant Sciences committing around US$349.90 million for 16,666,666 shares, reinforcing Immunovant's financing plans as it prepares for multiple pivotal clinical programs. We'll now examine how this large Roivant-backed capital raise, aimed at advancing IMVT-1402, influences Immunovant's broader investment narrative. Find companies with promising cash flow potential yet trading below their fair value To own Immunovant, you really have to believe that IMVT-1402 can become a meaningful autoimmune franchise and that the company can fund the long, loss-making road to that point. The fresh US$550.20 million equity raise, with Roivant putting in roughly US$349.90 million, directly addresses one of the key near term risks: running short of cash before pivotal readouts and a
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Roivant Sciences (NASDAQ:ROIV) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $24.00 to $33.00. They now have a "buy" rating on the stock.MarketBeat
- Roivant Sciences (NASDAQ:ROIV) had its "outperform" rating reaffirmed by analysts at Leerink Partners.MarketBeat
- Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor DayGlobeNewswire
- Immunovant drops 7%, prices $550M stock offering [Seeking Alpha]Seeking Alpha
ROIV
Earnings
- 11/10/25 - Beat
ROIV
Sec Filings
- 12/15/25 - Form 4
- 12/15/25 - Form 144/A
- 12/15/25 - Form 144
- ROIV's page on the SEC website